吉非替尼对不同肿瘤患者miR-21、miR-155的表达和PI3K/Akt通路的影响

Effect of gefitinib on miR-21,miR-155 expression and PI3K /Akt pathway in patients with three different tumor

目的探讨3组不同肿瘤患者血浆中miR-21、miR-155及组织中p-PI3K、p-Akt的表达及吉非替尼干预的影响。方法选取2011年3月~2014年2月在四川省人民医院血液肿瘤科收治的肿瘤患者75例,经病理确诊为食道癌28例(A组),胃癌25例(B组),非小细胞肺癌22例(C组),另选取56例无肿瘤人员作为对照组(分为D1、D2、D3组)。采用RT-PCR和Western blot检测吉非替尼干预前后患者血清及组织中miR-21、miR-155、p-PI3K、p-Akt的表达情况。结果 RT-PCR结果显示:与对照组相比,胃癌及非小细胞肺癌患者血浆中miR-21、miR-155表达明显升高(P<0.01),食道癌患者血浆miR-155表达明显升高(P<0.01),但miR-21表达无差异;采用吉非替尼干预后,胃癌及非小细胞肺癌患者血浆中miR-21、miR-155表达明显下降,差异有统计学意义(P<0.05),食道癌患者血浆中miR-155明显升高(P<0.05),miR-21表达无明显变化。Western blot结果显示:食道癌及胃癌患者组织中p-Akt的表达量明显高于对照组(P<0.01),但非小细胞肺癌患者组织中p-Akt的表达量与对照组相比差异无统计学意义;胃癌、非小细胞肺癌患者组织中p-PI3K的表达量明显高于对照组(P<0.05,P<0.01),但食道癌患者组织中p-PI3K的表达量与对照组相比差异无统计学意义。结论 miR-21、miR-155在3种不同肿瘤患者血浆中均呈高表达,吉非替尼干预后,能明显降低3种癌症细胞患者血浆中miR-21、miR-155的表达。

Objective To investigate the miR-21,miR-155 in three different tumor patients plasma and the expression of p-PI3K、p-Akt in tissue,then to study the intervention by gefitinib. Methods 75 cases patients with cancer were selected and treated in the Sichuan Provincial People's Hospital from March 2011 to February 2014,28 cases of esophagus cancer( A group),25 cases of gastric carcinoma( group B),22 cases of nonsmall-cell lung cancer( C group),the other 56 cases as control group( no tumor personnel divided into D1 D2,3,D group),the serum and tissue of patients with Western blot and RT-PCR detection in p-PI3 K,p-Akt and miR-21,miR-155 expression,and the results were statistically analyzed. Results Western blot results showed that: the expression of p-Akt in esophageal and gastric carcinoma patients was significantly higher,the difference was statistically significant( P < 0. 01),while expression of p-Akt of non-small cell lung cancer tissue compared with control group was no significant difference;expression of p-PI3 K in gastric cancer,non-small cell lung cancer tissue was higher,the difference was statistically significant( P < 0. 05,P < 0. 01);tissue expression levels of p-PI3 K in patients with esophageal cancer were compared with the control group,and the difference was not statistically significant. Compared with the control group,miR-21,miR-155 expression in plasma of gastric cancer and non-small cell lung cancer were higher,the difference was statistically significant( P < 0. 01),plasma miR-155 expression in patients with esophageal cancer were higher than control group( P <0. 01),but no differences in the expression of miR-21; after using gefitinib to intervene,miR-21,miR-155 expression in plasma of gastric cancer and non-small cell lung cancer was significantly decreased,and the difference was statistically significant( P < 0. 05),plasma miR-155 in patients with esophageal cancer was significantly higher( P < 0. 05),miR-21 expression did not change. Conclusion miR-21,miR-155 are highly expressed in three different patients with cancer,while gefitinib after intervention for patients with gastric cancer and non-small cell lung cancer effect is better,but for the intervention of esophagus cancer patients with somewhat less effect.